GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - protein search, using frame_plus_n2p model

Run on: August 17, 2004, 15:13:02 ; Search time 0.001 Seconds
(without alignments)
409.920 Million cell updates/sec

Title: us-09-270-437d-5
Perfect score: 3110
Sequence: 1 agggacgctgccgcaccgcc.....atttccttcaggttttaaaa 1708

Scoring table: BLOSUM62
Xgapop 10.0 , Xgapext 0.5
Ygapop 10.0 , Ygapext 0.5
Fgapop 6.0 , Fgapext 7.0
Delop 6.0 , Delext 7.0

Searched: 6 seqs, 120 residues

Total number of hits satisfying chosen parameters: 12

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 6 summaries

Command line parameters:
-MODEL=frame+_n2p.model -DEV=soft -Q=us-09-270-437d-5 -DB=*.geneseqp*
-SUFFIX=pto -OUT=align5 -MINMATCH=0.1 -LOOPCL=0 -LOOPEXT=0 -UNITS=bits
-START=1 -END=-1 -MATRIX=blosum62 -TRANS=human40.cdi -LIST=6 -DOCALIGN=200
-THR_SCORE=pct -THR_MAX=100 -THR_MIN=0 -ALIGN=6 -MODE=LOCAL -OUTFMT=pto
-NORM=ext -HEAPSIZE=500 -MINLEN=0 -MAXLEN=2000000000 -NCPU=6 -NO_XLPXY
-NEG_SCORES=0 -LONGLOG -THREADS=1 -XGAPOP=10 -XGAPEXT=0.5 -FGAPOP=6 -FGAPEXT=7
-YGAPOP=10 -YGAPEXT=0.5 -DELOP=6 -DELEXT=7

Database : *.geneseqp*:*
1: /home/sdavid/sdavid-tmp/aug04/canella437/abb75042.geneseqp2002s:*
2: /home/sdavid/sdavid-tmp/aug04/canella437/abb75041.geneseqp2002s:*
3: /home/sdavid/sdavid-tmp/aug04/canella437/abp61961.geneseqp2002s:*
4: /home/sdavid/sdavid-tmp/aug04/canella437/abp61962.geneseqp2002s:*
5: /home/sdavid/sdavid-tmp/aug04/canella437/ada28504.geneseqp2003bs:*
6: /home/sdavid/sdavid-tmp/aug04/canella437/ada28505.geneseqp2003bs:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | % Query Match | Length | DB | ID | Description |
|---|---|---|---|---|---|---|
| 1 | 101 | 3.2 | 20 | 1 | ABB75042 | Human lung tumour |
| 2 | 101 | 3.2 | 20 | 4 | ABP61962 | Human lung cancer |
| 3 | 101 | 3.2 | 20 | 6 | ADA28505 | Human lung tumour |
| 4 | 96 | 3.1 | 20 | 2 | ABB75041 | Human lung tumour |
| 5 | 96 | 3.1 | 20 | 3 | ABP61961 | Human lung cancer |
| 6 | 96 | 3.1 | 20 | 5 | ADA28504 | Human lung tumour |

ALIGNMENTS

RESULT 1
ABB75042
ID ABB75042 standard; peptide; 20 AA.
XX
AC ABB75042;
XX
DT 01-MAY-2002 (first entry)
XX
DE Human lung tumour L523S peptide SEQ ID NO:415.
XX
KW Human; lung tumour; lung cancer; cytostatic; immunostimulant; vaccine;
KW immune response.
XX
OS Homo sapiens.
XX
PN WO200200174-A2.
XX
PD 03-JAN-2002.
XX
PF 28-JUN-2001; 2001WO-US021065.
XX
PR 28-JUN-2000; 2000US-00606421.
PR 02-AUG-2000; 2000US-00630940.
PR 21-AUG-2000; 2000US-00643597.
PR 15-SEP-2000; 2000US-00662786.
PR 09-OCT-2000; 2000US-00685696.
PR 12-DEC-2000; 2000US-00735705.
PR 07-MAY-2001; 2001US-00850716.
XX
PA (CORI-) CORIXA CORP.
XX
PI Wang T, Wang A, Skeiky YAW, Li SX, Kalos MD, Henderson RA;
PI Mcneill PD, Fanger N, Retter MW, Marnerakis M, Fanger GR;
PI Vedvick TS, Carter D, Watanabe Y, Peckham DW;
XX
DR WPI; 2002-090513/12.
XX
PT Polynucleotides encoding lung tumor polypeptides, useful for treating
PT lung cancer or stimulating an immune response.
XX
PS Claim 2; Page 351; 374pp; English.
XX
CC The present invention describes human lung tumour proteins. Human lung
CC tumour proteins and polynucleotides have cytostatic and immunostimulant
CC activities, and can be used in vaccine production. Compositions
CC comprising the lung tumour proteins, polynucleotides, antibodies, fusion
CC proteins, T cell populations, or antigen presenting cells that express
CC the lung tumour proteins are useful for treating lung cancer or
CC stimulating an immune response. ABL48959 to ABL49300 and ABB74946 to
CC ABB75070 represent sequences used in the exemplification of the present
CC invention
XX
SQ Sequence 20 AA;

Alignment Scores:

| | | | |
|---|---|---|---|
| Pred. No.: | 1.61 | Length: | 20 |
| Score: | 101.00 | Matches: | 20 |
| Percent Similarity: | 100.00% | Conservative: | 0 |
| Best Local Similarity: | 100.00% | Mismatches: | 0 |
| Query Match: | 3.25% | Indels: | 0 |
| DB: | 1 | Gaps: | 0 |

us-09-270-437d-5 (1-1708) x ABB75042 (1-20)

```
Qy        293 AACATCACAAAACAGACCCAGTCCAAGATAGACGTGCATAGGAAGGAGAACGCAGGTGCA 352
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 AsnIleThrLysGlnThrGlnSerLysIleAspValHisArgLysGluAsnAlaGlyAla 20
```

RESULT 2
ABP61962
ID ABP61962 standard; peptide; 20 AA.
XX
AC ABP61962;
XX
DT 07-OCT-2002 (first entry)
XX
DE Human lung cancer associated peptide sequence SEQ ID NO:415.
XX

KW Human; lung cancer; lung tumour; cytostatic; gene therapy; vaccine.
XX
OS Homo sapiens.
XX
PN WO200247534-A2.
XX
PD 20-JUN-2002.
XX
PF 30-NOV-2001; 2001WO-US047576.
XX
PR 12-DEC-2000; 2000US-00735705.
PR 07-MAY-2001; 2001US-00850716.
PR 28-JUN-2001; 2001US-00897778.
XX
PA (CORI-) CORIXA CORP.
XX
PI Wang T, Wang A, Skeiky YAW, Li SX, Kalos MD, Henderson RA;
PI Mcneill PD, Fanger N, Retter MW, Durham M, Fanger GR, Vedvick TS;
PI Carter D, Watanabe Y, Peckham DW, Cai F, Foy TM;
XX
DR WPI; 2002-583465/62.
XX
PT Novel lung carcinoma polynucleotide sequences and polypeptides encoded by
PT the polynucleotides, useful in pharmaceutical compositions such as
PT vaccines and as markers to indicate the presence of lung cancer.
XX
PS Claim 9; Page 358; 381pp; English.
XX
CC The present invention describes isolated human lung carcinoma
CC polynucleotides (I) and polypeptides (II). (I) and (II) have cytostatic
CC activity, and can be used in gene therapy and in vaccines. Compositions
CC comprising (I) or (II) can be used for stimulating an immune response in
CC a patient and for treating lung cancer in a patient. Oligonucleotides of
CC (I) can be used for detecting the presence of a cancer in a patient, by
CC obtaining a biological sample from the patient, contacting the biological
CC sample with the oligonucleotide, detecting in the sample, an amount of
CC polynucleotide that hybridises to the oligonucleotide and comparing the
CC amount of polynucleotide that hybridises to the oligonucleotide to a
CC predetermined cut-off value, and determining the presence of a cancer in
CC the patient. (I) and (II) are useful in pharmaceutical compositions, e.g.
CC vaccines. (I) is useful as a marker to indicate the presence or absence
CC of a cancer such as lung cancer. ABQ92145 to ABQ92486 and ABP61866 to
CC ABP61992 represent sequences used in the exemplification of the present
CC invention
XX
SQ Sequence 20 AA;

Alignment Scores:

| | | | |
|---|---|---|---|
| Pred. No.: | 1.61 | Length: | 20 |
| Score: | 101.00 | Matches: | 20 |
| Percent Similarity: | 100.00% | Conservative: | 0 |
| Best Local Similarity: | 100.00% | Mismatches: | 0 |
| Query Match: | 3.25% | Indels: | 0 |
| DB: | 4 | Gaps: | 0 |

us-09-270-437d-5 (1-1708) x ABP61962 (1-20)

```
Qy        293 AACATCACAAAACAGACCCAGTCCAAGATAGACGTGCATAGGAAGGAGAACGCAGGTGCA 352
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 AsnIleThrLysGlnThrGlnSerLysIleAspValHisArgLysGluAsnAlaGlyAla 20
```

RESULT 3
ADA28505
ID ADA28505 standard; peptide; 20 AA.
XX
AC ADA28505;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human lung tumour associated protein L523S peptide #20.
XX
KW cancer; lung cancer; gene therapy; vaccine; human;
KW lung squamous cell carcinoma.
XX
OS Homo sapiens.
XX
PN US2003064947-A1.
XX
PD 03-APR-2003.
XX
PF 30-NOV-2001; 2001US-00007700.
XX
PR 18-MAR-1998; 98US-00040802.
PR 27-JUL-1998; 98US-00123912.
PR 22-DEC-1998; 98US-00221107.
PR 02-APR-1999; 99US-00285479.
PR 17-DEC-1999; 99US-00466396.
PR 30-DEC-1999; 99US-00476496.
PR 10-JAN-2000; 2000US-00480884.
PR 22-FEB-2000; 2000US-00510376.
PR 04-APR-2000; 2000US-00542615.
PR 28-JUN-2000; 2000US-00606421.
PR 02-AUG-2000; 2000US-00630940.
PR 21-AUG-2000; 2000US-00643597.
PR 15-SEP-2000; 2000US-00662786.
PR 09-OCT-2000; 2000US-00685696.
PR 12-DEC-2000; 2000US-00735705.
PR 07-MAY-2001; 2001US-00850716.
PR 28-JUN-2001; 2001US-00897778.
XX
PA (CORI-) CORIXA CORP.
XX
PI Wang T, Wang A, Skeiky YAW, Li SX, Kalos MD, Henderson RA;
PI Mcneill PD, Fanger N, Retter MW, Durham M, Fanger GR, Vedvick TS;
PI Carter D, Watanabe Y, Peckham DW, Cai F, Foy TM;
XX
DR WPI; 2003-540798/51.
XX
PT New isolated polynucleotides and polypeptides useful for diagnosing,
PT preventing and/or treating cancer, particularly lung cancer.
XX
PS Claim 9; Page 270-271; 296pp; English.
XX
CC The invention describes isolated polynucleotides and polypeptides useful
CC for diagnosing, preventing and/or treating cancer, particularly lung
CC cancer. A new isolated polynucleotide comprises: any of the 22 fully
CC defined nucleotide sequences (e.g. 1012, 900 or 2773 bp) given in the
CC specification; complements of the nucleotide sequences cited above; at
CC least 10 contiguous residues of the nucleotide sequences cited above; a
CC sequence that hybridise to any of the nucleotide sequences under highly
CC stringent conditions; a sequence that is at least 75 or 90% identical to
CC the above nucleotide sequences; or degenerate variants of the above
CC nucleotide sequences. The composition and methods are useful in
CC diagnosing, preventing and/or treating cancer, particularly lung cancer,
CC in gene therapy and in vaccines. This is the amino acid sequence of a
CC human lung tumour associated protein L523S peptide.
XX
SQ Sequence 20 AA;

Alignment Scores:

| | | | |
|---|---|---|---|
| Pred. No.: | 1.61 | Length: | 20 |
| Score: | 101.00 | Matches: | 20 |
| Percent Similarity: | 100.00% | Conservative: | 0 |
| Best Local Similarity: | 100.00% | Mismatches: | 0 |
| Query Match: | 3.25% | Indels: | 0 |
| DB: | 6 | Gaps: | 0 |

us-09-270-437d-5 (1-1708) x ADA28505 (1-20)

```
Qy        293 AACATCACAAAACAGACCCAGTCCAAGATAGACGTGCATAGGAAGGAGAACGCAGGTGCA 352
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 AsnIleThrLysGlnThrGlnSerLysIleAspValHisArgLysGluAsnAlaGlyAla 20
```

RESULT 4
ABB75041
ID ABB75041 standard; peptide; 20 AA.

good CRF, no separate hit in gene pg database or reading database

XX
AC ABB75041;
XX
DT 01-MAY-2002 (first entry)
XX
DE Human lung tumour L523S peptide SEQ ID NO:414.
XX
KW Human; lung tumour; lung cancer; cytostatic; immunostimulant; vaccine;
KW immune response.
XX
OS Homo sapiens.
XX
PN WO200200174-A2.
XX
PD 03-JAN-2002.
XX
PF 28-JUN-2001; 2001WO-US021065.
XX
PR 28-JUN-2000; 2000US-00606421.
PR 02-AUG-2000; 2000US-00630940.
PR 21-AUG-2000; 2000US-00643597.
PR 15-SEP-2000; 2000US-00662786.
PR 09-OCT-2000; 2000US-00685696.
PR 12-DEC-2000; 2000US-00735705.
PR 07-MAY-2001; 2001US-00850716.
XX
PA (CORI-) CORIXA CORP.
XX
PI Wang T, Wang A, Skeiky YAW, Li SX, Kalos MD, Henderson RA;
PI Mcneill PD, Fanger N, Retter MW, Marnerakis M, Fanger GR;
PI Vedvick TS, Carter D, Watanabe Y, Peckham DW;
XX
DR WPI; 2002-090513/12.
XX
PT Polynucleotides encoding lung tumor polypeptides, useful for treating
PT lung cancer or stimulating an immune response.
XX
PS Claim 2; Page 351; 374pp; English.
XX
CC The present invention describes human lung tumour proteins. Human lung
CC tumour proteins and polynucleotides have cytostatic and immunostimulant
CC activities, and can be used in vaccine production. Compositions
CC comprising the lung tumour proteins, polynucleotides, antibodies, fusion
CC proteins, T cell populations, or antigen presenting cells that express
CC the lung tumour proteins are useful for treating lung cancer or
CC stimulating an immune response. ABL48959 to ABL49300 and ABB74946 to
CC ABB75070 represent sequences used in the exemplification of the present
CC invention
XX
SQ Sequence 20 AA;

Alignment Scores:

| | | | |
|---|---|---|---|
| Pred. No.: | 1.87 | Length: | 20 |
| Score: | 96.00 | Matches: | 20 |
| Percent Similarity: | 100.00% | Conservative: | 0 |
| Best Local Similarity: | 100.00% | Mismatches: | 0 |
| Query Match: | 3.09% | Indels: | 0 |
| DB: | 2 | Gaps: | 0 |

us-09-270-437d-5 (1-1708) x ABB75041 (1-20)

```
Qy        263 ATTATTGGCAAGGAGGGGGCCACCATCCGCAACATCACAAAACAGACCCAGTCCAAGATA 322
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 IleIleGlyLysGluGlyAlaThrIleArgAsnIleThrLysGlnThrGlnSerLysIle 20
```

RESULT 5
ABP61961
ID ABP61961 standard; peptide; 20 AA.
XX
AC ABP61961;
XX
DT 07-OCT-2002 (first entry)
XX
DE Human lung cancer associated peptide sequence SEQ ID NO:414.
XX
KW Human; lung cancer; lung tumour; cytostatic; gene therapy; vaccine.
XX
OS Homo sapiens.
XX
PN WO200247534-A2.
XX
PD 20-JUN-2002.
XX
PF 30-NOV-2001; 2001WO-US047576.
XX
PR 12-DEC-2000; 2000US-00735705.
PR 07-MAY-2001; 2001US-00850716.
PR 28-JUN-2001; 2001US-00897778.
XX
PA (CORI-) CORIXA CORP.
XX
PI Wang T, Wang A, Skeiky YAW, Li SX, Kalos MD, Henderson RA;
PI Mcneill PD, Fanger N, Retter MW, Durham M, Fanger GR, Vedvick TS;
PI Carter D, Watanabe Y, Peckham DW, Cai F, Foy TM;
XX
DR WPI; 2002-583465/62.
XX
PT Novel lung carcinoma polynucleotide sequences and polypeptides encoded by
PT the polynucleotides, useful in pharmaceutical compositions such as
PT vaccines and as markers to indicate the presence of lung cancer.
XX
PS Claim 9; Page 358; 381pp; English.
XX
CC The present invention describes isolated human lung carcinoma
CC polynucleotides (I) and polypeptides (II). (I) and (II) have cytostatic
CC activity, and can be used in gene therapy and in vaccines. Compositions
CC comprising (I) or (II) can be used for stimulating an immune response in
CC a patient and for treating lung cancer in a patient. Oligonucleotides of
CC (I) can be used for detecting the presence of a cancer in a patient, by
CC obtaining a biological sample from the patient, contacting the biological
CC sample with the oligonucleotide, detecting in the sample, an amount of
CC polynucleotide that hybridises to the oligonucleotide and comparing the
CC amount of polynucleotide that hybridises to the oligonucleotide to a
CC predetermined cut-off value, and determining the presence of a cancer in
CC the patient. (I) and (II) are useful in pharmaceutical compositions, e.g.
CC vaccines. (I) is useful as a marker to indicate the presence or absence
CC of a cancer such as lung cancer. ABQ92145 to ABQ92486 and ABP61866 to
CC ABP61992 represent sequences used in the exemplification of the present
CC invention
XX
SQ Sequence 20 AA;

Alignment Scores:

| | | | |
|---|---|---|---|
| Pred. No.: | 1.87 | Length: | 20 |
| Score: | 96.00 | Matches: | 20 |
| Percent Similarity: | 100.00% | Conservative: | 0 |
| Best Local Similarity: | 100.00% | Mismatches: | 0 |
| Query Match: | 3.09% | Indels: | 0 |
| DB: | 3 | Gaps: | 0 |

us-09-270-437d-5 (1-1708) x ABP61961 (1-20)

```
Qy        263 ATTATTGGCAAGGAGGGGGCCACCATCCGCAACATCACAAAACAGACCCAGTCCAAGATA 322
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 IleIleGlyLysGluGlyAlaThrIleArgAsnIleThrLysGlnThrGlnSerLysIle 20
```

RESULT 6
ADA28504
ID ADA28504 standard; peptide; 20 AA.
XX
AC ADA28504;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human lung tumour associated protein L523S peptide #19.
XX

KW cancer; lung cancer; gene therapy; vaccine; human;
KW lung squamous cell carcinoma.
XX
OS Homo sapiens.
XX
PN US2003064947-A1.
XX
PD 03-APR-2003.
XX
PF 30-NOV-2001; 2001US-00007700.
XX
PR 18-MAR-1998; 98US-00040802.
PR 27-JUL-1998; 98US-00123912.
PR 22-DEC-1998; 98US-00221107.
PR 02-APR-1999; 99US-00285479.
PR 17-DEC-1999; 99US-00466396.
PR 30-DEC-1999; 99US-00476496.
PR 10-JAN-2000; 2000US-00480884.
PR 22-FEB-2000; 2000US-00510376.
PR 04-APR-2000; 2000US-00542615.
PR 28-JUN-2000; 2000US-00606421.
PR 02-AUG-2000; 2000US-00630940.
PR 21-AUG-2000; 2000US-00643597.
PR 15-SEP-2000; 2000US-00662786.
PR 09-OCT-2000; 2000US-00685696.
PR 12-DEC-2000; 2000US-00735705.
PR 07-MAY-2001; 2001US-00850716.
PR 28-JUN-2001; 2001US-00897778.
XX
PA (CORI-) CORIXA CORP.
XX
PI Wang T, Wang A, Skeiky YAW, Li SX, Kalos MD, Henderson RA;
PI Mcneill PD, Fanger N, Retter MW, Durham M, Fanger GR, Vedvick TS;
PI Carter D, Watanabe Y, Peckham DW, Cai F, Foy TM;
XX
DR WPI; 2003-540798/51.
XX
PT New isolated polynucleotides and polypeptides useful for diagnosing,
PT preventing and/or treating cancer, particularly lung cancer.
XX
PS Claim 9; Page 270; 296pp; English.
XX
CC The invention describes isolated polynucleotides and polypeptides useful
CC for diagnosing, preventing and/or treating cancer, particularly lung
CC cancer. A new isolated polynucleotide comprises: any of the 22 fully
CC defined nucleotide sequences (e.g. 1012, 900 or 2773 bp) given in the
CC specification; complements of the nucleotide sequences cited above; at
CC least 10 contiguous residues of the nucleotide sequences cited above; a
CC sequence that hybridise to any of the nucleotide sequences under highly
CC stringent conditions; a sequence that is at least 75 or 90% identical to
CC the above nucleotide sequences; or degenerate variants of the above
CC nucleotide sequences. The composition and methods are useful in
CC diagnosing, preventing and/or treating cancer, particularly lung cancer,
CC in gene therapy and in vaccines. This is the amino acid sequence of a
CC human lung tumour associated protein L523S peptide.
XX
SQ Sequence 20 AA;

Alignment Scores:

| | | | |
|---|---|---|---|
| Pred. No.: | 1.87 | Length: | 20 |
| Score: | 96.00 | Matches: | 20 |
| Percent Similarity: | 100.00% | Conservative: | 0 |
| Best Local Similarity: | 100.00% | Mismatches: | 0 |
| Query Match: | 3.09% | Indels: | 0 |
| DB: | 5 | Gaps: | 0 |

us-09-270-437d-5 (1-1708) x ADA28504 (1-20)

```
Qy        263 ATTATTGGCAAGGAGGGGGCCACCATCCGCAACATCACAAAACAGACCCAGTCCAAGATA 322
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 IleIleGlyLysGluGlyAlaThrIleArgAsnIleThrLysGlnThrGlnSerLysIle 20
```

Search completed: August 17, 2004, 15:13:03
Job time : 1 secs